Cel-Sci Corporation
CVMStock
$1.15−67.42%52W
Market Cap$18.88M
P/E—
Div yield—
Beta0.62
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-89.28%
Price vs S&P 500 (4W)13.26%
VGM Score21.27
Market Capitalization$18.88M
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CVMCel-Sci Corporation | D | — | F | $1.15 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
CEL-SCI Corp is a late-stage biotechnology company developing immunotherapies designed to leverage the immune system against cancer and autoimmune diseases. Its lead program, Multikine, is in Phase 3 clinical trials for head and neck cancer. The company is also advancing its LEAPS technology platform for potential treatment of rheumatoid arthritis.